Compare BIO-TECHNE Corp (TECH) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.37. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| TECH | TMF | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.48 | $44.14 |
52-Week Low | $43.31 | $29.83 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $30.85, down 0.13% for the day, with a bearish technical signal driven by moving averages. The stock faces significant long-term erosion, as highlighted by a recent article showing a $10,000 investment five years ago would now be worth about $1,527. Key support lies at $30, with resistance at $31.
The outlook remains challenged by interest rate sensitivity and leverage decay, posing risks for investors seeking Treasury exposure. Opportunities may arise from potential Federal Reserve policy shifts, but volatility and structural ETF risks demand caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
